The amount of the protein, NR2F1, present indicates whether a breast cancer patient will likely relapse and develop deadly bone metastases
The Ion GeneStudio S5 series' multichip design offers flexibility, while Oncomine portfolio adds liquid biopsy and immuno-oncology assays
PlasmaSELECT will be the first plasma-based genomic profiling test offered to VA cancer patients, and the first to also include MSI testing.
Lung cancer is one of the most common malignancies and the leading cause of cancer-related fatality. In the United States alone, more than 210,000...
New research will be presented at the 2017 annual meeting of the American Association for Cancer Research (AACR).
The combined offering is aimed at addressing the limitations of tissue-based PD-L1 testing that can hamper immunotherapy clinical trials
Janssen will use BiomX's XMarker platform to stratify responders versus non-responders of inflammatory bowel disease therapeutics
A variety of malignant outliers may hide in transcriptome profiles that emphasize averages.
It was inspiring to listen to Howard J. Jacob, Ph.D., professor of physiology and human and molecular genetics at Medical College of Wisconsin, speaking...
Companies to partner on biomarkers for Oncologie's pipeline, which includes the Phase III lefitolimod and the Phase II bavituximad